Evidence Table N3: DISCRETE outcomes for class OTHER.

Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

N.01.02 Gugulipid Tetracycline

Severity change (michaelsson) Excellent 3 0.05

Good 7

Poor 0

Excellent 2

Good 6

Poor 2

325

Parallel Sev

N=20

È Mid (12)

Post-therapy relapse Relapse 2

No relapse 8

Relapse 4

No relapse 6

Long (96

N.01.03 Isolutrol Benzoyl peroxide

Burning Present 1 0.05

Absent 34

Present 12

Absent 23

94

Parallel 

Mild/mod

N=70

Mid (12)

Dryness Present 11 0.05

Absent 24

Present 29

Absent 6

Mid (12)

Erythema Present 3 0.05

Absent 32

Present 17

Absent 18

Mid (12)

Pruritis Present 5 0.05

Absent 30

Present 15

Absent 20

Mid (12)

Scaling Present 3 0.005

Absent 32

Present 25

Absent 10

Mid (12)

N.01.04 Ocimum basilicum Tetracycline

Severity change (grade) 100% reduction 0

>50% reduction 20

<50% reduction 3

No reduction 0

100% reduction 0

>50% reduction 14

<50% reduction 3

No reduction 6

Increase 3

17

Parallel 

N=51

Í Mid (8)

Increase 2

N.01.05 Tea tree oil Benzoyl peroxide

Unwanted effects Present 27 0.001

Absent 31

Present 50

Absent 13

18

Parallel Mod

N=124

È Mid (12)

N.02.01 Clobetasol Vehicle

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table N DISCRETE: Page 1 of 10

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Severity change Overall reduction in active lesions NS

6

Overall increase in active lesions 2

Little change 3

Overall reduction in active lesions 1

Overall increase in active lesions 0

Little change 10

175

Parallel split 

face Mod

N=11

È Short (3)

N.02.04 Neomycin + methyl prednisolone Vehicle

Overall change/physician Improved 355 0.001

Not improved 69

Improved 76

Not improved 75

228

Parallel 

N=776

Short (5)

Methyl prednisolone + neomycin 

+ sulfur

N.02.05 Vehicle

Overall change Excellent 29 0.02

Good 22

Same 13

Worse 2

Excellent 16

Good 20

Same 27

Worse 5

102

Parallel 

N=134

È

N.02.06 Neomycin + methyl prednisolone Aluminum chlorhydroxide + sulfur

Overall change/physician Improved 355 0.001

Not improved 69

Improved 142

Not improved 59

228

Parallel 

N=776

Short (5)

N.03.01 Gamma-globulin Placebo

Overall change/physician None 5

Fair 4

Good 7

Very good 8

None 1

Fair 3

Good 8

Very good 4

189

Parallel 

Mod/sev

N=40

Long (80

Side effects Long (80 Pain 2 Pain 0

N.03.03 Staphylococcal toxoid Vehicle

Adverse reation Colds with fever 10

Axillary adenitis 2

Colds with fever 2

Axillary adenitis 0

222

Parallel 

Mild/mod/sev

N=66

È Short (1)

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table N DISCRETE: Page 2 of 10

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Overall change/patient Cure complete 0

Great improvement 5

Partial improvement 16

No improvement 12

Cure complete 0

Great improvement 0

Partial improvement 5

No improvement 25

Worse 2

222

Parallel 

Mild/mod/sev

N=66

È Mid (10)

Worse 1

Overall change/physician [mild] Improved 9

Not improved 5

Improved 3

Not improved 4

Mid (10)

Overall change/physician [moderate] Improved 9

Not improved 6

Improved 10

Not improved 12

Mid (10)

Overall change/physician [severe] Improved 5

Not improved 0

Improved 2

Not improved 1

Mid (10)

Overall change/patient Cure complete 0

Great improvement 8

Partial improvement 15

No improvement 11

Cure complete 0

Great improvement 2

Partial improvement 13

No improvement 16

Worse 1

Long (24

Worse 0

Overall change/physician [mild] Improved 7

No 7

Improved 1

No 6

Long (24

Overall change/physician [moderate] Improved 11

Not improvement 4

Improvement 4

Not improvement 18

Long (24

Overall change/physician [severe] Improved 3

Not improved 2

Improved 0

Not improved 3

Long (24

Chloramphenicol + 

hydrocortisone

N.04.01 Vehicle

Overall change/patient Definitely better 12 0.05

Possibly better 2

No change 0

Worse 0

Definitely better 6

Possibly better 5

No change 3

Worse 0

Missing 1

297

Parallel 

Mild/mod

N=32

Short (4)

Missing 1

Overall change/physician Definitely better 12

Possibly better 1

No change 1

Worse 0

Definitely better 6

Possibly better 4

No change 4

Worse 0

Missing 1

Short (4)

Missing 1

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table N DISCRETE: Page 3 of 10

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Severity (burton) 0 0 0.05

1 8

2 5

3 1

0 0

1 1

2 12

3 1

No record 1

297

Parallel 

Mild/mod

N=32

Short (4)

No record 1

Overall change/patient Definitely better 10 0.05

Possibly better 2

No change 1

Worse 0

Definitely better 4

Possibly better 1

No change 7

Worse 2

Missing 1

Mid (8)

Missing 2

Overall change/physician Definitely better 10

Possibly better 2

No change 1

Worse 0

Definitely better 4

Possibly better 2

No change 5

Worse 3

Missing 1

Mid (8)

Missing 2

Severity (burton) 0 0

1 12

2 1

3 0

0 0

1 6

2 4

3 4

No record 1

Mid (8)

No record 2

Withdrawals due to side effects Withdraw 0 0.014

Did not withdraw 15

Withdraw 5

Did not withdraw 10

Mid (8)

Hydrocortisone + buttoxethyl 

nicotinate + chloramp

N.04.02 Vehicle

Side effects 224 Itchiness/ dryness 5 Itchiness/ dryness 3

Cross-over 

Mild/mod/sev

N=120

È Mid (10)

Chloramphenicol + 

hydrocortisone + sulfur

N.04.03 Chloramphenicol + sulfur

Overall change/patient Improved 22 NS

Not improved or worse 0

Improved 21

Not improved or worse 1

142

Parallel 

Mild/mod

N=50

Short (4)

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table N DISCRETE: Page 4 of 10

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Overall change/physician Improved 22 NS

Not improved or worse 0

Improved 22

Not improved or worse 0

142

Parallel 

Mild/mod

N=50

Short (4)

Overall change/patient Improved 13 NS

Not improved or worse 9

Improved 14

Not improved or worse 8

Mid (12)

Overall change/physician Improved 11 NS

Not improved or worse 11

Improved 15

Not improved or worse 7

Mid (12)

Chloramphenicol + 

hydrocortisone + sulfur

N.04.04 Hydrocortisone + sulfur

Overall change/patient Improved 14

Same 2

Worse 0

No data 0

Improved 12

Same 8

Worse 1

No data 0

115

Parallel 

N=37

È Short (4)

Overall change/physician Improved 14

Same 2

Worse 0

No data 0

Improved 15

Same 5

Worse 1

No data 0

Short (4)

Local reactions Mid (12) Irritant and poor cosmesis 0 Irritant and poor cosmesis 1

Overall change/patient Improved 8

Same 3

Worse 2

No data 3

Improved 7

Same 6

Worse 3

No data 5

Mid (12)

Overall change/physician Improved 9

Same 2

Worse 2

No data 3

Improved 7

Same 6

Worse 4

No data 4

Mid (12)

Chloramphenicol + 

hydrocortisone + sulfur

N.04.05 Benzoyl peroxide

75 Erythema Necessitating treatment reduction 5 Necessitating treatment reduction 2

Parallel Mod

N=48

È Mid (12)

Scaling Mid (12) Necessitating treatment reduction 4 Necessitating treatment reduction 6

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table N DISCRETE: Page 5 of 10

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

N.05.01 Grenz rays Sham rays

Post-therapy overall state/observer Better 10

Same 19

Worse 4

Better 4

Same 19

Worse 10

138

Parallel split 

face 

N=40

È Mid (7)

Post-therapy overall state/observer Better 14

Same 14

Side 1

Better 1

Same 14

Side 14

Mid (9)

Post-therapy overall state/observer Better 9

Same 12

Worse 2

Better 2

Same 12

Worse 9

139

Parallel split 

face 

N=33

È Mid (7)

Post-therapy overall state/observer Better 12

Same 14

Worse 2

Better 2

Same 14

Worse 12

Mid (9)

Post-therapy overall state/observer Better 1

Same 8

Worse 1

Better 1

Same 8

Worse 1

Long (16

Improvement Worse 1

Unchanged 15

Improved 10

Greatly improved 12

Worse 2

Unchanged 16

Improved 12

Greatly improved 8

179

Parallel split 

face 

N=40

Short (5.

Severity change (group %) Worse 3

Unchanged 9

Improved 16

Greatly improved 18

Worse 3

Unchanged 13

Improved 18

Greatly improved 8

180

Parallel split 

face 

N=42

Short (4)

Comedone extraction 

(cheeks/forehead)

N.05.02 Untreated

Inflammatory change Better 8

Worse 4

Better 4

Worse 8

216

Parallel split 

face 

N=12

È Long (24

N.06.04 Hydrochlorthiazide Placebo

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table N DISCRETE: Page 6 of 10

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Overall change Usual 12

Less 4

Better 9

Usual 18

Less 0

Better 7

284

Parallel 

N=50

Í Mid (8)

N.06.04 Hydrochlorthiazide Vehicle

Premenstrual overall change/patient 

[phase ii]

Poor 11

Fair 3

Good 6

Excellent 1

Poor 6

Fair 4

Good 7

Excellent 4

178

Cross-over 

N=42

Í Short (4)

Premenstrual overall change/physician 

[phase i]

Reduced 7

Not reduced 14

Reduced 12

Not reduced 9

Short (4)

Adverse reactions/No withdrawals Headache 20

Unresolved edema 3

Headache 15

Unresolved edema 6

Mid (8)

Adverse reactions/Withdrawals Itching 1

Dizziness and heartburn 1

Nausea 1

Weakness 1

Itching 0

Dizziness and heartburn 0

Nausea 0

Weakness 0

Fainting/lethargy 1

Mid (8)

Fainting/lethargy 0

Premenstrual change/patient [phase ii] Poor 5

Fair 10

Good 5

Excellent 1

Poor 10

Fair 5

Good 5

Excellent 3

Mid (8)

Premenstrual overall change/physician 

[phase ii]

Reduced 8

Not reduced 13

Reduced 8

Not reduced 13

Mid (8)

N.06.05 Tolbutamide Vehicle

Overall change/patient Worse 0

Same 5

Improved 8

Worse 1

Same 6

Improved 10

110

Parallel 

Mod/sev

N=30

È Mid (12)

Overall change/physician Worse 0

Same 6

Improved 7

Worse 0

Same 7

Improved 10

Mid (12)

Severity/photo Worse 2

Same 6

Improved 5

Worse 2

Same 6

Improved 9

Mid (12)

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table N DISCRETE: Page 7 of 10

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

N.07.02 Zinc Placebo

91 Nausea Nausea 3 Nausea 3

Parallel Mod

N=66

È

Severity/patient Improvement-none 12 0.002

Improvement-slight 11

Improvement-marked 9

Improvement-none 22

Improvement-slight 8

Improvement-marked 4

Mid (8)

Severity/photo Improvement-none 8 0.0001

Improvement-slight 12

Improvement -marked 12

Improvement-none 26

Improvement-slight 5

Improvement-marked 3

Mid (8)

N.07.02 Zinc sulfate Placebo

Overall change/physician Better 8

No change 3

Worse 6

Better 7

No change 6

Worse 5

3

Parallel 

N=42

Mid (12)

GI distress Nausea/vomiting (withdraw) 6

Nausea/vomiting (remained) 5

Diarrhea 3

Nausea/vomiting (withdraw) 0

Nausea/vomiting (remained) 1

Diarrhea 0

341

Parallel 

Mild/mod

N=52

È Mid (12)

N.07.02 Zinc sulfate Vehicle

Oilness No change 12

Less oiliness/seborrhea 17

No change 27

Less oiliness/seborrhea 0

336

Parallel Mod

N=56

È Short (6)

Severity change Excellent 3

Moderate 10

Slight 1

Very slight 11

Excellent 12

Moderate 3

Slight 2

Very slight 10

Aggravation 2

Short (6)

Aggravation 2

Side effects Nausea/withdraw 1

Nausea 3

None 25

Nausea/withdraw 0

Nausea 0

None 27

Short (6)

Side effects Nausea/ vomiting (withdraw) 2

Nausea/ vomiting (no withdraw) 3

Nausea/ vomiting (withdraw) 0

Nausea/ vomiting (no withdraw) 0

342

Parallel Mod

N=39

È

N.07.02 Zinc suphate Placebo

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table N DISCRETE: Page 8 of 10

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Withdrawal due to side effects Nausea & vomiting 1 NS

Diarrhea 1

Fatigue & headache 0

Pruritis 1

Nausea & vomiting 2

Diarrhea 1

Fatigue & headache 1

Pruritis 0

163

Parallel 

Mod/sev

N=112

Overall change/patient Much improved 11 0

Improved 14

Somewhat improved 13

Unchanged 7

Much improved 8

Improved 5

Somewhat improved 15

Unchanged 9

Worse 3

Much worse 0

Short (4)

Worse 1

Much worse 0

Overall change/physician Much improved 9 NS

Improved 17

Somewhat improved 11

Unchanged 5

Much improved 7

Improved 8

Somewhat improved 13

Unchanged 7

Worse 5

Much worse 0

Short (4)

Worse 3

Much worse 1

Overall change/patient Much improved 23 0.02

Improved 13

Somewhat improved 7

Unchanged 4

Much improved 14

Improved 8

Somewhat improved 12

Unchanged 7

Worse 2

Much worse 0

Mid (12)

Worse 1

Much worse 0

Overall change/physician Much improved 20 0.01

Improved 18

Somewhat improved 2

Unchanged 6

Much improved 13

Improved 10

Somewhat improved 8

Unchanged 8

Worse 4

Much worse 0

Mid (12)

Worse 2

Much worse 0

Side effects Slight nausea initially 2 NS

Vomiting 1

Gastric discomfort 1

Dryness of mouth 1

Slight nausea initially 0

Vomiting 0

Gastric discomfort 0

Dryness of mouth 0

Slight gastric discomfort 1

Nausea 1

Mid (12)

Slight gastric discomfort 0

Nausea 0

N.08.02 Erythromycin + zinc Erythromycin

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table N DISCRETE: Page 9 of 10

ÈÍ
Trial #

Method Info

Discrete Outcome Name (Units)

Definition/Comments

Between

P-value

Follow- Treatment Comparator

up (wks)

Comparison Attribute: Number of patient Attribute: Number of patients

Local side effects Withdraw 2

Mild 11

Withdraw 2

Mild 6

147

Parallel Mod

N=122

È

N.08.03 Erythromycin + zinc Clindamycin phosphate

Cutaneous Burning/redness/withdraw 1

Irritation 0

Absent 47

Burning/redness/withdraw 0

Irritation 1

Absent 43

300

Parallel Mod

N=103

TRIAL: -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN 

P-VALUE: comparison between Target and Comparator arms.

Evidence Table N DISCRETE: Page 10 of 10

ÈÍ